09:49 AM EST - BioVaxys Technology Corp : Announced today that it has entered into an agreement with the Deaconess Research Institute to supply BioVaxys with surgically debulked tumors from Stage III/Stage IV ovarian cancer patients undergoing treatment at Deaconess Health System. DRI, based in Evansville, Indiana, is the clinical studies arm of Deaconess, a premier regional provider of health care services in the United States. Access to ovarian cancer tumor cells is a critical step enabling BioVaxys to validate the manufacturing process for BVX-0918, the Company's autologous haptenized tumor cell vaccine for late-stage ovarian cancer. BioVaxys Technology Corp
shares C.BIOV are trading down one cent at $0.13.
